Scientists uncover immune cells that may trigger type 1 diabetes years early

A breakthrough in type 1 diabetes (T1D) research has uncovered a unique group of immune cells that may trigger the disease long before symptoms appear. Scientists at the Perelman School of Medicine identified these cells in the pancreatic lymph nodes of people with active T1D. The findings suggest a way to detect—and possibly halt—the condition earlier than ever before.

The research team discovered a distinct subset of CD4 T-cells in patients with active T1D. These same cells were also present in individuals at high risk of developing the disease, indicating that the immune system's attack on insulin-producing cells starts well before diagnosis. By the time most people are diagnosed, the majority of their insulin-making cells have already been destroyed.

The problematic CD4 T-cells produce elevated levels of two proteins, NFKB1 and BACH2. These proteins act like master switches, accelerating the immune system's assault on the pancreas. Their presence could serve as an early warning sign of T1D.

Since the study's publication in early 2024, clinical trials have made rapid progress. Biomarker testing, including validation through networks like TrialNet (2024–2026), has shown promise. A 2025 Oxford-led Phase II study reported an 85% sensitivity rate in detecting pre-symptomatic T1D through simple blood tests.

The discovery of these immune cells and their linked proteins opens a new path for early detection. With ongoing trials validating biomarkers, doctors may soon screen at-risk individuals before irreversible damage occurs. This could transform how T1D is diagnosed and treated in the future.